Answers are grounded in this paper and cite their sources.
Objective To describe the patterns of use, annual rate, characteristics and safety in children receiving continuous propofol infusions. Design Retrospective study from 1st January 2017 to 31st December 2024. Setting Tertiary paediatric intensive care unit (PICU). Participants Children aged 18 years or younger who received a continuous propofol infusion in the PICU for greater than 1 h between 2017 and 2024. Main outcome measures Annual proportion of admissions receiving propofol. Results There were 2903/12,392 (23%) PICU admissions receiving a continuous propofol infusion during the study period. The annual rate of propofol administration doubled from 268/1730 (15.5%) of PICU admissions in 2017 to 453/1522 (29.8%) in 2024. Children who received propofol were older (5.0 years [interquartile range {IQR}; 1.0 to 11.0] vs 1.0 years [IQR; 0.0 to 7.0]; p < 0.001). The median starting dose was 2 mg/kg/hr and the median duration (time from first to last hour) was 0.6 days (IQR; 0.4 to 1.2), with a maximum of 21 days. Creatine kinase and triglyceride tests, as potential markers of propofol-related adverse events, were performed in 364/2903 (12.5%) of admissions within the first eight days. There were no documented cases of propofol infusion syndrome, and mortality in those that received propofol was 62/2903 (2.1%) compared to 290/9524 (3.0%) in those who did not. Conclusions In a single-centre study, continuous propofol infusions were administered to 23% of admissions, and the annual rate doubled over the study period. Propofol was more commonly administered at a low dose, for a short duration. Serious adverse effects of propofol were not identified.
No takes yet. Share an insight, caveat, or question.
Athreya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: